NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ligand.comThe patent US9993461 for FILSPARI, a dual angiotensin and endothelin receptor antagonist used for treating various diseases, is set to expire on March 29, 2030. This expiration is significant as it may affect the competitive landscape for Ligand Pharmaceuticals Inc and Travere Therapeutics Inc, possibly allowing for the entry of generic alternatives into the market.
Patent Expiration